Brazil’s new medical cannabis rules reject domestic cultivation, potentially setting up large import market

  • Brazil’s National Sanitary Surveillance Agency (ANVISA) discusses new rules for medical cannabis in the country.
  • Brazilian health authorities rejected domestic cultivation of medical marijuana but agreed to permit the distribution of medicinal cannabis products that have not completed clinical trials, potentially setting up one of the largest import markets in the world.
  • The new rules, adopted Tuesday, allow bulk imports and sales in pharmacies for the first time.
  • This week’s decision by the collegiate directory of ANVISA – the Brazilian Agência Nacional de Vigilância Sanitária, or National Sanitary Surveillance Agency – in effect rejected a proposal to allow domestic cultivation but created transitional rules to facilitate the commercialization of cannabis products.
  • GW Pharmaceuticals’ Sativex is currently the only registered cannabis medicine in Brazil, but the new rules will allow a separate registration of ” cannabis products” that have not undergone clinical trials.

Read full article: